Mapracorat

Mapracorat (INN, code names BOL-303242-X, ZK-245186^[1]) is an anti-inflammatory drug belonging to the experimental class of selective glucocorticoid receptor agonists (SEGRAs). It is in clinical trials for the topical treatment of atopic dermatitis,^[2] inflammation following cataract surgery,^[3] and allergic conjunctivitis.^[4] Preliminary investigation for the treatment of keratoconjunctivitis sicca has been conducted in cellular models.^[1]

Mapracorat

Clinical data
Routes of administration	Topical (ointment, eye drops)
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol
CAS Number	887375-26-0 Y
PubChem CID	24795088
ChemSpider	25104194 N
UNII	145V79YBVP
KEGG	D10136 N
CompTox Dashboard (EPA)	DTXSID401029572
ECHA InfoCard	100.217.969
Chemical and physical data
Formula	C25H26F4N2O2
Molar mass	462.489 g·mol−1
3D model (JSmol)	Interactive image
SMILES c14OCCc4cc(F)cc1C(C)(C)CC(O)(C(F)(F)F)CNc(cccc2n3)c2ccc3C
InChI InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1 N Key:VJGFOYBQOIPQFY-XMMPIXPASA-N N
NY (what is this?)  (verify)

Clinical trials

Phase II clinical trials with mapracorat started in summer 2009. One trial was a double blind dose finding study for an ointment against atopic dermatitis. It tested concentrations of 0.01%, 0.03% and 0.1% versus placebo over four weeks in around 64 patients. This trial was conducted by Intendis, a part of Bayer HealthCare Pharmaceuticals specialized on dermatology, and completed in September or October 2010.^[2] The other trial, also with a double blind design, evaluated an ophthalmic suspension for the treatment of inflammation following cataract surgery. Various concentrations and dosing schemes were tested versus placebo in about 550 patients. The study was conducted by Bausch & Lomb and completed in September 2010.^[3] Its successor study, a phase III trial, started in November 2010 and completed in August 2011.^[5]

As of January 2017^[update] no study results are available.

See also

• AZD-5423
• Dagrocorat
• Fosdagrocorat